loader image

Our Mission

To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.

Pipeline

Drawing upon our extensive experience in developing therapeutics for chronic liver diseases and viral infections, we are building a pipeline of potentially best-in-class drug candidates.  These drug candidates target multiple clinically validated mechanisms of action and are designed to achieve high rates of functional cure for CHB and become transformative treatment options for COVID-19 and NASH.

Management Team

Our management team brings together years of experience and expertise with the goal of making Aligos a world leader in developing targeted therapies for hepatologic diseases and viral infections that affect millions of people around the world.

Our Mission

To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.

Join the Aligos TeamJoin our growing team in developing targeted therapies for liver diseases like chronic hepatitis B and NASH.

Join the Aligos Team

Join our growing team in developing targeted therapies for liver diseases like chronic hepatitis B nd NASH.

Scientific Overview

We are engaged in the discovery and development of purpose-built, potentially best in class oligonucleotide and small molecule drug candidates which target clinically validated mechanisms of action in CHB, coronavirus infections and NASH. 

Coronavirus
Coronavirus

COVID-19 Update

As a biotechnology company consisting of employees with longstanding experience in viral therapeutics development, we believe that we have a responsibility and unique expertise to determine whether our technologies may yield promising therapeutic candidates for COVID-19.  To this end, we have expanded an existing license agreement with Luxna Biotech Inc., Ltd., which grants us exclusive rights to the use of Luxna’s innovative modified nucleic acid technology to target the genomes of certain viruses, including SARS-CoV-2, the virus causing COVID-19. 

Additionally, we have entered into a collaboration and license agreement with KU Leuven’s Centre for Drug Design and Discovery (CD3) and the Rega Institute for Medical Research to develop a coronavirus protease inhibitor as a potential therapeutic candidate.